Scroll
To Top

Patient-Centered, Data-Driven Advocacy

NORD_RareInsights_Logo_FNLRareInsights™ is a NORD initiative to expand public knowledge of rare diseases and translate that knowledge into real-world solutions for patients and families.

Through this initiative, NORD is commissioning and undertaking a broad range of projects to collect and analyze empirical data for next-generation advocacy that is patient-centered and data-driven. Information is shared with the community in a variety of accessible formats, including reports, white papers, infographics, fact sheets, and more.

Patient-Centered, Data-Driven Advocacy

Partnerships

If you or your organization are interested in partnering with NORD on a RareInsights study or publication, please contact us at lsarfaty@rarediseases.org.

Latest Release

The Orphan Drug Act (ODA) of 1983 is a federal law that incentivizes biopharmaceutical companies to develop drugs and biologics, know as “orphan drugs,” for individuals with rare diseases. Prior to the ODA, there were only 34 therapies indicated to treat a rare disease. Now, there are over 700 and counting!

Learn more about the Orphan Drug Act in this RareInsights fact sheet.

Today, there are still many misconceptions about orphan drugs and about the Orphan Drug Act.  Download the newly released study by the IQVIA Institute, “Orphan Drugs in the United States: Growth Trends in Rare Disease Treatments,” which finds that despite a record-breaking number of new approvals, orphan drugs remain a nominal part of overall drug spending, accounting for only 9.6% of total sales in the U.S. in 2017. Click here for a one-page information sheet highlighting the study’s key findings.

Download Full Report from IQVIA Institute

Download the Rare Disease Factsheet.

 

NORD_5myths_about_orphan_drugs

Download the 5 Myths About the Orphan Drug Act and Orphan Drugs infographic.

NORD_IMS_Report_cover

Download Trends in Orphan Drug Costs and Expenditures Do Not Support Revisions in the Orphan Drug Act: Background and History. (2017)

QuintilesIMS_report_cover

Download Orphan Drugs in the United States: Providing Context for Use and Cost. (2017)

ImpactOfODTaxCredit_cover

Download Impact of Orphan Drug Tax Credit on Treatments for Rare Diseases. Published by NORD and BIO (2015).

Quant_Effectiveness_of_OD_cover

Download Quantum of Effectiveness Evidence in FDA’s Approval of Orphan Drugs: Cataloguing FDA’s Flexibility in Regulating Therapies for Persons with Rare Disorders. Published by Frank J. Sasinowski, M.S., M.P.H., J.D., former Chairman of the Board for NORD (2011).